<DOC>
	<DOCNO>NCT00589238</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , doxorubicin , cyclophosphamide , carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether combination chemotherapy effective without carboplatin treat breast cancer . PURPOSE : This randomized phase II trial study give paclitaxel together doxorubicin cyclophosphamide see well work compare give paclitaxel together doxorubicin , cyclophosphamide , carboplatin treat woman locally advance breast cancer remove surgery .</brief_summary>
	<brief_title>Paclitaxel , Doxorubicin , Cyclophosphamide With Or Without Carboplatin Treating Women With Locally Advanced Breast Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate tumor pathological complete response rate neoadjuvant paclitaxel v without carboplatin follow cyclophosphamide doxorubicin hydrochloride woman basal-type subtype primary breast cancer . Secondary - To evaluate clinical pathological overall response rate . - To evaluate safety toxicity . - To evaluate disease-free survival overall survival . - To correlate low BRCA1 expression ( protein mRNA ) , p53 mutation , positive CK5/6 , positive CK 14 , basal-like gene expression profile , response carboplatin-based treatment . OUTLINE : This multicenter study . Patients stratify accord clinical stage ( T2-3 v T4 ) . Patients randomize 1 2 treatment arm . - Arm I ( standard therapy ) : Patients receive paclitaxel IV 1 hour weekly week 1-12 . Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 , 8 , 15 . Treatment doxorubicin hydrochloride cyclophosphamide repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Arm II ( experimental therapy ) : Patients receive paclitaxel IV 1 hour carboplatin IV 15 20 minute day 1 , 8 , 15 . Treatment paclitaxel carboplatin repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients receive doxorubicin hydrochloride cyclophosphamide arm I . All patient undergo surgical resection tumor . Patients undergo biopsy correlative study . Samples analyze estrogen receptor progesterone receptor status , molecular endpoint ( CK 5/6 , CK14 , p53 , BRCA , EGFR ) RT-PCR , immunohistochemistry , protein expression , gene expression profile . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive basaltype breast cancer meeting follow criterion : Newly diagnose disease Locally advance operable primary disease &gt; 2 cm , without evidence metastatic disease Clinical T2 ( &gt; 2 cm ) , T3 ( &gt; 5 cm ) , T4 primary tumor without clinical lymph node involvement ( N03 ) T4 tumor define follow : Skin ulceration Satellite nodules Peau ' orange ( skin edema ) Chest wall invasion Inflammatory breast cancer Her2/neu 01+ IHC ( negative fluorescent situ hybridization Her2 2+ immunohistochemistry ) No metastatic disease Hormone receptor status : Estrogen progesterone receptornegative disease PATIENT CHARACTERISTICS : Inclusion criterion : Female Menopausal status specify ECOG performance status ( PS ) 02 Karnofsky PS 60100 % Life expectancy &gt; 10 year Leukocytes ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/μL Total bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Fertile patient must use effective contraception Cardiac ejection fraction ≥ 50 % assessed MUGA scan 2D echocardiogram Exclusion criterion : History allergic reaction attribute compound similar chemical biologic composition paclitaxel , carboplatin , agent use study Preexisting peripheral neuropathy Uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement Prior malignancy except basal cell carcinoma skin curatively treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No HIVpositive patient receive combination antiretroviral therapy No concurrent primary growth factor prophylaxis No concurrent investigational agent No concurrent chemotherapy , immunotherapy , hormonal cancer therapy , surgery cancer , experimental medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>